Study identifier:D1443L00086
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A comparison of the effectiveness of Seroquel XR and Seroquel XR plus lithium in patients with acute bipolar mania: An open-label, randomized, parallel groups, rater-blinded, 4 week, multicenter, comparative, phase 4 study
Acute bipolar mania
Phase 4
No
Quetiapine fumarate, lithium
All
131
Interventional
18 Years - 65 Years
Allocation: Randomized 
Endpoint Classification: Safety Study 
Intervention Model: Parallel Assignment 
Masking: Open Label 
Primary Purpose: Treatment 
Verified 01 Oct 2013 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|---|
| Experimental: 1 Seroquel XR tablet | Drug: Quetiapine fumarate  eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study. | 
| Active Comparator: 2 Seroquel XR + lithium | Drug: Quetiapine fumarate  eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study. Drug: lithium  300mg tablet, oral |